Business

InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conf...

articleInfield Minerals CorpAugust 31, 20183/company/infield-minerals-corp-1/news/inmed-pharmaceuticals-to-present-at-the-hc-wainwright-20th-annual-global-investment-conference
InMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference

About this update from Infield Minerals Corp

[{"type":"text","content":"\n\n\n\nInMed Pharmaceuticals to Present at the H.C. Wainwright 20th Annual Global Investment Conference\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, Aug. 31, 2018\n\n\n\nTSX:INOTCQX:IMLFF\n\n\n\nVANCOUVER, Aug. 31, 2018 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a fully integrated, cannabinoid-based biopharmaceutical company that leverages its proprietary bioinformatics and biosynthesis platform technologies to develop novel therapeutics for the treatment of diseases with high unmet medical needs, today announced that Josh Blacher, Chief Business Officer of InMed, will be presenting at the H.C. Wainwright 20th Annual Global Investment Conference on Thursday, September 6th at 3:50 PM Eastern Time at The St. Regis New York Hotel.\n\n\n \n \n\n \nThe presentation will be available on InMed's website.\n\nAbout InMed:InMed is a pre-clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed's proprietary bioinformatics database drug/disease targeting tool, cannabinoid biosynthesis technology and drug development pipeline are the fundamental value drivers of the Company. For more information, visit www.inmedpharma.com\n\nAbout Epidermolysis Bullosa (EB).  EB is a group of rare diseases that cause fragile, blistering skin.  The blisters may appear in response to minor injury, even from heat, rubbing, scratching or adhesive tape.  In severe cases, the blisters may occur inside the body, such as the lining of the mouth or the stomach.  Most types of epidermolysis bullosa are inherited.  The condition usually presents in infancy or early childhood.  Epidermolysis bullosa has no cure.\n\nAbout INM-750.  INM-750 is a proprietary, topical cannabinoid product candidate targeted as a therapy in epidermolysis bullosa (EB) and other potential dermatological and wound-healing applications. It has been specificall...

More updates from Infield Minerals Corp